Consistently, direct activation of either ErbB3 or EGFR signaling with specific ligands (NRG-1 and EGF, respectively) also resulted in significant abrogation of anti-pancreatic cancer activity of VPA (Fig. 4e-i). This evidence concerns the gene ERBB3 and pancreatic neoplasm.